Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$0.47 USD
+0.06 (14.68%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $0.46 -0.01 (-2.65%) 7:16 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALGS 0.47 +0.06(14.68%)
Will ALGS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALGS
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
Other News for ALGS
Aligos Therapeutics Shareholders Back Key Corporate Resolutions
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Moderna (MRNA) and Aligos Therapeutics (ALGS)
Aligos Therapeutics presents data from ALG-000184 at EASL
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024